Amgen posts results for terminated acapatamab mCRPC trial; updates MARITIME-PEN and AMG 691 recordsNov 13Weekly roundup, 6 itemsacapatamabAMG-691Updated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
New Phase 2a trial registered for Amgen's xaluritamig after lutetium-177 therapyJul 30Trial updateAmgenxaluritamig